NCT06767735View on ClinicalTrials.gov

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects with Type 2 Diabetes Mellitus (T2DM)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

February 2, 2026

Study Completion Date

August 17, 2026

Conditions
Diabetes
Interventions
DRUG

GZR4

GZR4 s.c., once-weekly，treat-to-target dose

DRUG

Insulin Glargine U100

Insulin Glargine U100 s.c.,once-daily，treat-to-target dose

Sponsors
All Listed Sponsors
lead

Gan & Lee Pharmaceuticals.

INDUSTRY